Positron buys Cadenza software

AuntMinnie.com staff writers

Jun 8, 2006

PET vendor Positron has acquired exclusive licensing rights to sell and further develop Cadenza Software for predicting coronary artery disease.

Cadenza Software, which was developed by Dr. George Diamond, employs Bayes' theorem to analyze and report results of various clinical descriptors and noninvasive tests for the diagnosis of coronary artery disease, according to the Houston-based firm.

By AuntMinnie.com staff writers
June 9, 2006

Related Reading

Positron shows IS2 camera after acquisition, June 7, 2006

Positron buys gamma camera firm IS2, June 6, 2006

Positron signs up Mexico distribution, May 23, 2006

Positron adds PET cardiology software, April 12, 2006

Positron gets Health Canada nod, March 22, 2006

Positron opens Chinese joint venture, February 13, 2006

Copyright © 2006 AuntMinnie.com

Kidneys appear to tolerate Lu-177 treatments

December 19, 2024

Theranostics for neuroendocrine tumors: Glenda’s journey

Theranostics for neuroendocrine tumors: Glenda’s journey

December 1, 2024

F-18 FLT-PET imaging of gastrointestinal GVHD. Examples of F-18 FLT uptake in a participant with no GVHD (left) and a participant with acute GVHD and uptake in the jejunum and ileum (right). Arrows denote increased uptake in the GI tract. Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of RSNA.

PET visualizes acute graft vs. host disease

December 16, 2024

PET/CT images of F-18 AlF-NOTA-BCP137 in patients with hepatocellular carcinoma (HCC) and immunofluorescence analysis of patient tissues. (A) F-18 AlF-NOTA-BCP137 PET/CT images before and after immunotherapy for patient 1 and patient 2. (B) F-18 AlF-NOTA-BCP137 PET/CT and MR images of patient 3 (left panels) after one cycle of immunotherapy. PET images showed higher uptake by tumor and spleen, and PET result was evaluated as positive; therefore, the patient was considered to be responder to treatment and underwent surgical resection. Representative images of hematoxylin and eosin (HE) staining and multiplex immunofluorescence of CD8 and CD137 (right panels) in HCC tumor and adjacent normal tissues of patient 3 after surgery. Nuclei were stained with 4′,6-diamidino-2-phenylindole. Primary tumors are indicated by white arrows, and increased thyroid uptake is indicated by red arrow in PET images. Image courtesy of the Journal of Nuclear Medicine.

Immuno-PET tracer shows promise in patients with liver cancer

December 12, 2024

Kidneys appear to tolerate Lu-177 treatments

Kidney-absorbed doses of lutetium-177 (Lu-177)-based treatments for prostate cancer and neuroendocrine tumors appear to be below toxicity thresholds.

December 19, 2024

African American men respond more favorably to Ra-223 therapy

African American men with metastatic castrate-resistant prostate cancer may respond more favorably than white men to treatment with radium-223.

December 17, 2024

Prostate Imaging

PET visualizes acute graft vs. host disease

F-18 fluorothymidine PET can identify early acute gastrointestinal graft versus host disease after patients undergo bone marrow transplants.

December 16, 2024

F-18 FLT-PET imaging of gastrointestinal GVHD. Examples of F-18 FLT uptake in a participant with no GVHD (left) and a participant with acute GVHD and uptake in the jejunum and ileum (right). Arrows denote increased uptake in the GI tract. Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of RSNA.

Immuno-PET tracer shows promise in patients with liver cancer

A new PET radiotracer has the potential for visualizing responses in liver cancer patients undergoing immunotherapy.

December 12, 2024

PET/CT images of F-18 AlF-NOTA-BCP137 in patients with hepatocellular carcinoma (HCC) and immunofluorescence analysis of patient tissues. (A) F-18 AlF-NOTA-BCP137 PET/CT images before and after immunotherapy for patient 1 and patient 2. (B) F-18 AlF-NOTA-BCP137 PET/CT and MR images of patient 3 (left panels) after one cycle of immunotherapy. PET images showed higher uptake by tumor and spleen, and PET result was evaluated as positive; therefore, the patient was considered to be responder to treatment and underwent surgical resection. Representative images of hematoxylin and eosin (HE) staining and multiplex immunofluorescence of CD8 and CD137 (right panels) in HCC tumor and adjacent normal tissues of patient 3 after surgery. Nuclei were stained with 4′,6-diamidino-2-phenylindole. Primary tumors are indicated by white arrows, and increased thyroid uptake is indicated by red arrow in PET images. Image courtesy of the Journal of Nuclear Medicine.

MGH's Mahmood named new RSNA president

By AuntMinnie.com staff writers

Mahmood's primary research for the past 30 years has been in molecular imaging and its application to guide precision medicine.

December 6, 2024

Rsna Mahmood Thumbnail

New SPECT-based coronary risk score developed for women

A new risk score based on SPECT imaging and other variables can accurately predict risks for women of major adverse cardiovascular events.

December 6, 2024

Heart Infection

PET/CT superior to CT in detecting bone metastases

F-18 FDG-PET/CT performs better and is more cost-effective than CT in determining biopsy sites for suspected bone metastases.

November 26, 2024

PET scan times can be reduced in Alzheimer’s patients

F-18 florbetaben PET scans for diagnosing Alzheimer’s disease can be reduced from 20 minutes to five minutes without losing accuracy.

November 25, 2024

Patient Elderly Confused Headache

PET links chronic stress to aggressive endometrial cancer

Brain activity related to chronic stress may be associated with the aggressiveness of tumors in women with endometrial cancer.

November 19, 2024

Pet Amygdala Thumbnail

FAPI-PET/CT superior to FDG-PET/CT in assessing liver cancer

A recent study suggests that PET/CT imaging with a FAPI radiotracer is superior to F-18 FDG-PET/CT for assessing patients with liver cancer.

November 18, 2024

Two cases of pathologically confirmed intrahepatic cholangiocarcinomas in 68-year-old male patients. In both cases (A-H, case 1; I-P, case 2), CT scans (B, F, case 1; J, N, case 2) revealed intrahepatic bile duct dilation and suspected nodular lesions. While F-18 FDG PET/CT (A, C, D, case 1; I, K, L, case 2) failed to demonstrate abnormal tracer uptake (SUVmax 3.5, TBR 1.3 in Case 1; SUVmax 2.6, TBR 1.2 in Case 2), F-18 FAPI-04 PET/CT (E, G, H, case 1; M, O, P, case 2 ) showed positive uptake in the nodular lesions (SUVmax 9.7, TBR 3.5 in Case 1; SUVmax 9.6, TBR 3.3 in Case 2). Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of BMC Cancer.

New PET tracer shows promise in patients with kidney cancer

A new PET radiotracer could offer a viable strategy for detecting primary tumors, involved lymph nodes, and distant metastases in patients with clear cell renal cell carcinoma.

November 14, 2024

Representative maximum-intensity projections of five patients (patients 3, 5, 7, 10, and 11) comparing Ga-68 NYM046 and F-18 FDG. Both tracers showed specific retention in bone and lymph node metastases (patients 10 and 11). Ga-68 NYM046 PET/CT outperformed F-18 FDG PET/CT in detecting primary tumors, lung metastases, and pleural metastases (patients 3, 5, 7, and 11). Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of the Journal of Nuclear Medicine.

SPECT/CT predicts treatment response in Pluvicto patients

SPECT/CT scans taken just four hours after patients begin Lu-177 PSMA-617 treatment can help assess treatment responses.

November 1, 2024

Pluvicto Spect Ct Response Thumbnail

Page 1 of 599